Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Affiliations

¹ Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
² Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Jhanelle.Gray@moffitt.org.
³ Jilin Provincial Cancer Hospital, Changchun, China.
⁴ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁶ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁷ Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan.
⁸ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁹ Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
¹⁰ Oncology R&D, AstraZeneca, Cambridge, UK.
¹¹ Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
¹² Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Published Erratum

Juliann Chmielecki et al. Nat Commun. 2023.

. 2023 Jun 1;14(1):3179.

doi: 10.1038/s41467-023-38999-0.

¹ Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
² Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Jhanelle.Gray@moffitt.org.
³ Jilin Provincial Cancer Hospital, Changchun, China.
⁴ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁶ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁷ Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan.
⁸ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
⁹ Kent Oncology Centre, Maidstone Hospital, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
¹⁰ Oncology R&D, AstraZeneca, Cambridge, UK.
¹¹ Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
¹² Winship Cancer Institute, Emory University, Atlanta, GA, USA.

No abstract available

Erratum for

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, Lin MC, Majem M, Shah R, Rukazenkov Y, Todd A, Markovets A, Barrett JC, Hartmaier RJ, Ramalingam SS. Chmielecki J, et al. Nat Commun. 2023 Feb 27;14(1):1070. doi: 10.1038/s41467-023-35961-y. Nat Commun. 2023. PMID: 36849494 Free PMC article.